고위험군 인유두종바이러스 검출에 있어AMPLICOR HPV Test와Hybrid Capture 2 Assay의 비교
Comparison of the AMPLICOR human papillomavirus (HPV)Test and the Hybrid Capture 2 Assayfor detection of high-risk HPV
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
=목적: 본 연구에서는 최근에 소개된 중합효소연쇄반응(polymerase chain reaction, PCR)법으로 target DNA를 증폭하여 고위험군 HPV를 검출하는 AMPLICOR HPV test와 기존에 시행되어 왔던 Hybrid Capture 2 (이하 HC2으로 기술함) assay를 비교하여 임상적 유용성을 평가하고자 하였다. 방법: 질확대경 클리닉에서 자궁경부암 검사를 시행하였던 153명의 환자를 대상으로 하였다. 결과: 고위험군 HPV 검사에서 AMPLICOR HPV test에서 양성이었던 경우는 53/153 (34.6%)이었으며 HC2 assay에서 양성이었던 경우는 52/153 (34.0%)이었다. 두 검사 간에 결과가 일치했던 경우는 128예 (83.7%)로 통계학적으로 의미있는 일치도를 보였다(Cohen’s kappa=0.63, p<0.001). 두 검사 간에 결과가 다른 경우 HPV genotyping을 확인한 결과 AMPLICOR HPV test에서 음성, HC2 assay에서 양성인 군에서 고위험군 HPV는 검출되지 않았으며 AMPLICOR HPV test에서 양성, HC2 assay에서 음성인 13예 중 3예 (23.1%)에서 고위험군 HPV가 발견되었다. 자궁경부질세포진 검사에 따른 HPV 양성률은 고등급병변으로 진행됨에 따라 두 가지 검사 모두에서 고위험군 HPV 양성 비율이 증가되는 경향을 보였다 (p<0.001). 조직학적으로 진단된 110예에서 고위험군 HPV 양성 비율은 CIN 1에서 AMPLICOR HPV test 결과 38.7%, HC2 assay 결과 48.4%에서 양성으로 나타났으며 CIN3/cancer에서는 AMPLICOR HPV test에서 95.0%, HC2 assay에서 100%의 양성률을 보여 고등급병변으로 진행됨에 따라 두 가지 검사 모두에서 고위험군 HPV 양성 비율이 증가되는 경향을 보였다 (p<0.001). 조직학적 검사로 진단된 CIN 2 이상의 고등급병변을 기준으로 민감도와 특이도를 구한 결과 AMPLICOR HPV test에서 민감도는 90.9% (신뢰구간 75.9~97.0%), 특이도는 72.7% (신뢰구간 64.3~79.8%)였고 HC2 assay에서 민감도는 95.5% (신뢰구간 81.9~99.0%), 특이도는 69.3% (신뢰구간 60.7~76.7%)였다. AMPLICOR HPV test와 HC2 assay간에 민감도와 특이도는 의의있는 차이는 없었다.
참고문헌 (36)
- 보건복지부 편집부, "암발생 통계(1999-2001)" (2005), 보건복지부
- Saslow D, "American cancer society guideline for the early detection of cervical neoplasia and cancer", CA cancer J Clin, 52, pp.342~362 (2002)
- Hai-Rim Shin, "2002 Annual Report of the Korea Central Cancer Registry: Based on Registered Data from 139 Hospitals", Cancer Research and Treatment, 36(2), pp.103~114 (2004), 대한암학회
- Soost HJ, "Ruffing-Kullmann B. The validation of cervical cytology. Sensitivity, specificity and predictive values", Acta Cytol, 35, pp.8~14 (1991)
- Dewar MA, "Cervical cancer screening. Past success and future challenge", Prim Care, 19, pp.589~606 (1992)
- Koss LG, "Cervical(Pap) smear. New directions", Cancer, 71(4), pp.1406~1412 (1993)
- Lieu D, "The Papanicolaou smear; its value and limitations", J Fam Pract, 42, pp.391~399 (1996)
- Miller AB, "Report on consensus conference on cervical cancer screening and management", Int J Cancer, 86, pp.440~447 (2000)
- Monsonego J, "Cervical cancer control, priorities and new directions", Int J cancer, 108, pp.329~333 (2004)
- Stafl A, "Cervicography: A new method for cervical cancer detection", Am J Obstet Gynocol, 139, pp.815~825 (1981)
- Hocutt GE Jr, "Papanicolaou testing and colposcopic screening", J Fam Pract, 34, pp.38~40 (1992)
- Burke L, "Cervicography: An alternative modality of cervical screening", Diagn Cytopathol, 7, pp.631~632 (1991)
- Schiffman MH, "Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia", J Natl Cancer Inst, 85, pp.958~964 (1993)
- Berek JS, "Practical gynecologic oncology", pp.278~283 (2000), Lippincott Williams & Wilkins
- Walboomers JM, "Human papillomavirus is a necessary cause of invasive cervical cancer worldwide", J Pathol, 189, pp.12~19 (1999)
- Clifford GM, "Human papillomavirus types in invasive cervical cancer worldwide: a meta- analysis", Br J Cancer, 88, pp.63~73 (2003)
- Park JS, "Detection of human papillomavirus genotypes in cervical neoplasia from Korean women using polymerase chain reaction", Gynecol Oncol, 41, pp.129~134 (1991)
- Bosch FX, "Risk factors for cervical cancer in Colombia and Spain", Int J Cancer, 52, pp.750~758 (1992)
- Sasagawa T, "A new PCR-based assay amplifies the E6-E7 genes of most mucosal human papillomaviruses (HPV)", Virus Res, 67, pp.127~139 (2000)
- Crook T, "p53 point mutation in HPV negative human cervical carcinoma cell lines", Oncogene, 6, pp.873~875 (1991)
- Wright TC Jr, "Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening", Obstet Gynecol, 103, pp.304~309 (2004)
- Schiffman M, "ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants", Acta Cytol, 44, pp.726~742 (2000)
- Koss LG, "The Papanicolaou test for cervical cancer detection. A triumph and a tragedy", JAMA, 261, pp.737~743 (1989)
- Godfroid E, "Detection and identification of human papilloma viral DNA, types 16, 18, and 33, by a combination of polymerase chain reaction and colorimetric solid phase capture hybridization assay", J Virol Methods, 75, pp.69~81 (1998)
- Zheng PS, "Simultaneous detection by consensus multiplex PCR of high- and low-risk and other types of human papilloma virus in clinical samples", Gynecol Oncol, 58, pp.179~183 (1995)
- Sandri MT, "Comparison of the Digene HC2 assay and the Roche AMPLICOR Human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples", J Clin Microbiol, 44, pp.2141~2146 (2006)
- De Francesco MA, "Comparison of the AMPLICOR human papillomavirus test and the hybrid capture 2 assay for detection of high-risk human papillomavirus in women with abnormal PAP smear", J Virol Methods, 147, pp.10~17 (2008)
- Halfon P, "Prospective evaluation of the Hybrid Capture 2 and AMPLICOR human papillomavirus (HPV) tests for detection of 13 high-risk HPV genotypes in atypical squamous cells of uncertain significance", J Clin Microbiol, 45, pp.313~316 (2007)
- Poljak M, "Retrospective and prospective evaluation of the Amplicor HPV test for detection of 13 high-risk human papillomavirus genotypes on 862 clinical samples", Acta Dermatovenerol Alp Panonica Adriat, 14, pp.147~152 (2005)
- Carozzi F, "Agreement between the AMPLICOR human papillomavirus test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy- confirmed high grade cervical disease", J Clin Microbiol, 45, pp.364~369 (2007)
- Stevens MP, "Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results", J Clin Microbiol, 45, pp.2130~2137 (2007)
- Castle PE, "Restricted cross- reactivity of hybrid capture 2 with nononcogenic human papillomavirus types", Cancer Epidemiol Biomarkers Prev, 11, pp.1394~1399 (2002)
- Poljak M, "Hybrid Capture II HPV Test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail", J Clin Virol, 25, pp.S89~S97 (2002)
- van Ham MA, "Comparison of two commercial assay for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders", J Clin Microbiol, 43, pp.2662~2667 (2005)
- Monsonego J, "Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear", ynecol. Oncol, 99, pp.160~168 (2005)
- 임수빈, "자궁경부 세포진 검사 미확정 비정형 편평세포에서 HPV DNA chip검사의 임상적 유용성", 대한산부인과학회잡지, 46(12), pp.16~16 (2003), 대한산부인과학회
